Equities analysts forecast that Orexigen Therapeutics, Inc. (NASDAQ:OREX) will announce ($2.06) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Orexigen Therapeutics’ earnings. Orexigen Therapeutics reported earnings per share of ($2.67) in the same quarter last year, which would indicate a positive year-over-year growth rate of 22.8%. The business is scheduled to announce its next earnings results on Tuesday, March 27th.

According to Zacks, analysts expect that Orexigen Therapeutics will report full-year earnings of ($10.08) per share for the current fiscal year. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that follow Orexigen Therapeutics.

A number of brokerages have commented on OREX. ValuEngine raised Orexigen Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Zacks Investment Research raised Orexigen Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th.

An institutional investor recently raised its position in Orexigen Therapeutics stock. Wells Fargo & Company MN raised its position in Orexigen Therapeutics, Inc. (NASDAQ:OREX) by 2.5% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,638 shares of the biopharmaceutical company’s stock after buying an additional 1,100 shares during the quarter. Wells Fargo & Company MN owned 0.30% of Orexigen Therapeutics worth $132,000 at the end of the most recent reporting period. 29.86% of the stock is currently owned by institutional investors and hedge funds.

Shares of Orexigen Therapeutics (NASDAQ:OREX) traded up $0.03 during midday trading on Friday, reaching $1.21. The company’s stock had a trading volume of 374,876 shares, compared to its average volume of 1,031,867. The company has a current ratio of 2.00, a quick ratio of 1.71 and a debt-to-equity ratio of -2.75. Orexigen Therapeutics has a 52-week low of $0.79 and a 52-week high of $4.48. The firm has a market cap of $22.85, a price-to-earnings ratio of -0.12 and a beta of 1.96.

COPYRIGHT VIOLATION WARNING: “Orexigen Therapeutics, Inc. (OREX) Expected to Post Earnings of -$2.06 Per Share” was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/orexigen-therapeutics-inc-orex-expected-to-post-earnings-of-2-06-per-share/1907218.html.

Orexigen Therapeutics Company Profile

Orexigen Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition.

Get a free copy of the Zacks research report on Orexigen Therapeutics (OREX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Orexigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orexigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.